SE
Insider
Staffan Encrantz
DirectorStaffan Encrantz (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Sight Sciences, Inc. (SGHT). Across 1 priced purchase filing, the average 21-session return was -20.6% from execution and -25.6% from disclosure (delay-adjusted; derived). The largest single filing was $116K of SGHT (13,958 sh × $8.31, as filed), executed Dec 16 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-20.6%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-25.6%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$116K
shares × price, as filed
Last traded
Dec 16 2025
Filed Dec 18 2025
Median ADV $1.8M across their filed names
Impact on $10,000 · 12M
$7,437 (-25.6%)
S&P 500 $11,725 (+17.2%) · 42.9 pts behind
Staffan Encrantz
S&P 500
Compounded across filings from disclosure dates · past 12 months
Open performance→Volume by month
Buys $3.2M
Sells $2.1M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
SGHTRecent filings
SGHTPURCHASE
Sight Sciences, Inc.
View filing →
$116K13,958 sh × $8.31
Exec Dec 16 2025
Filed Dec 18 2025 · 6:10 PM ET SGHTPURCHASE Sight Sciences, Inc. View filing → $291K
68,851 sh across 2 lots
Exec Jun 5 2025
Filed Jun 6 2025 · 5:30 PM ET SGHTPURCHASE Sight Sciences, Inc. View filing → $377K
98,782 sh across 3 lots
Exec May 30 2025
Filed Jun 3 2025 · 5:30 PM ET SGHTPURCHASE Sight Sciences, Inc. View filing → $358K
101,474 sh across 2 lots
Exec May 27 2025
Filed May 29 2025 · 5:30 PM ET SGHTSALE Sight Sciences, Inc. View filing → $2.1M
551,802 sh × $3.73
Exec Nov 21 2024
Filed Nov 21 2024 · 5:30 PM ET SGHTPURCHASE Sight Sciences, Inc. View filing → $2.1M
551,802 sh × $3.73
Exec Nov 21 2024
Filed Nov 21 2024 · 5:30 PM ET